Molecular hydrogen as a treatment for ME/CFS: a mini-review of clinical evidence and mechanistic rationale.
Fred Friedberg, Tyler W LeBaron · Frontiers in medicine · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined the available molecular-hydrogen literature. Molecular hydrogen (H₂), administered primarily as hydrogen-rich water (HRW), has emerged as a potential therapeutic candidate due to its selective antioxidant effects, anti-inflammatory activity, and support of mitochondrial and cellular homeostasis. Key limitations include small sample sizes, reliance on self-report outcomes, and the absence of objective biomarkers. The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
What the Findings Mean
H2HUBB reviewed this publication as a synthesis of molecular-hydrogen research and summarizes the outcomes emphasized by the authors. Molecular hydrogen (H₂), administered primarily as hydrogen-rich water (HRW), has emerged as a potential therapeutic candidate due to its selective antioxidant effects, anti-inflammatory activity, and support of mitochondrial and cellular homeostasis.
What the Researchers Studied
The authors reviewed molecular hydrogen as a treatment for ME/CFS: a mini-review of clinical evidence and mechanistic rationale.
What Effects Did Molecular Hydrogen Have?
Integrating such biomarker assessments into remote HRW trials would help to determine whether the physiological effects attributed to hydrogen are reflected in ME/CFS patients and clarify the mechanisms underlying the preliminary clinical benefits observed to date. To reach limited-mobility patients, hydrogen water is a feasible, low burden intervention that is easily adapted to home-based administration. Molecular hydrogen (H₂), administered primarily as hydrogen-rich water (HRW), has emerged as a potential therapeutic candidate due to its selective antioxidant effects, anti-inflammatory activity, and support of mitochondrial and cellular homeostasis. The authors concluded that key limitations include small sample sizes, reliance on self-report outcomes, and the absence of objective biomarkers. Initial studies suggest potential benefits in reducing fatigue and improving overall symptom burden, consistent with molecular hydrogen’s reported antioxidant and anti-inflammatory properties.
Why These Findings Matter
The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
How Strong Is This Evidence?
This is review or synthesis evidence (narrative review).
Technical Study Details
H2HUBB classifies this publication as narrative review with review or synthesis evidence. The study used a narrative review. The hydrogen delivery method was hydrogen-rich water.
Limitations and Safety
Reported limitations: Key limitations include small sample sizes, reliance on self-report outcomes, and the absence of objective biomarkers.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.